Robert Blanks, MS RAC
About Robert Blanks, MS RAC
Robert Blanks, MS RAC, is the Chief Regulatory Affairs & Quality Assurance Officer with over 20 years of experience in the pharmaceutical industry, specializing in quality, regulatory, and CMC areas.
Robert Blanks, MS RAC - Current Role
Robert Blanks currently serves as the Chief Regulatory Affairs & Quality Assurance Officer. With more than 20 years of experience in the pharmaceutical industry, he brings extensive expertise in quality, regulatory, and Chemistry, Manufacturing, and Controls (CMC) areas. In his role, Robert ensures that products meet stringent quality standards and comply with all regulatory requirements from development through to commercialization.
Robert Blanks Education and Certifications
Robert Blanks holds a Bachelor of Science degree in Biology from Bowdoin College and a Master of Science degree in Chemistry from Boston College. He is also Regulatory Affairs Certified (RAC), highlighting his comprehensive understanding and commitment to regulatory standards and practices in the pharmaceutical industry.
Robert Blanks - Industry Experience
Robert Blanks has a rich history in the pharmaceutical industry, having held key positions at multiple companies. He was Vice President of CMC at Flexion Therapeutics, overseeing the manufacture of initial drug product candidates, including Zilretta™. At Idenix Pharmaceuticals, he was Vice President of Quality, leading all quality aspects for the commercial launch of Tyzeka®. He has also served as Vice President of Technical Operations for Trine Pharmaceuticals and was a founder and VP of Technical Operations at Phaedrus Pharmaceuticals.
Robert Blanks Contributions to Drug Development
Throughout his career, Robert Blanks has played a crucial role in the development of initial drug product candidates, spanning peptides, monoclonal antibodies, and small molecules. His expertise has been instrumental in guiding these products from the pre-clinical stage to commercial registration. Notably, he contributed to the development and registration of RenaGel® at GelTex Pharmaceuticals, a project that later paved the way for the company's acquisition by Genzyme.